Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors

被引:14
作者
Zhang, Hai-Liang [1 ,2 ]
Sheng, Xi-Nan [3 ]
Li, Xue-Song [4 ]
Wang, Hong-Kai [1 ,2 ]
Chi, Zhi-Hong [3 ]
He, Zhi-Song [4 ]
Ye, Ding-Wei [1 ,2 ]
Guo, Jun [3 ]
机构
[1] Fudan Univ, Shanghai Canc Ctr, Dept Urol, Shanghai 200032, Peoples R China
[2] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China
[3] Peking Univ, Canc Hosp & Inst, Dept Renal Canc & Melanoma, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing, Peoples R China
[4] Peking Univ, Dept Urol, Hosp 1, Inst Urol,Natl Urol Canc Ctr, Beijing, Peoples R China
基金
中国国家自然科学基金;
关键词
Metastatic renal cell carcinoma; Sorafenib; Sunitinib; Prognosis; Survival; BLIND PHASE-III; TARGETED THERAPY; EXPANDED-ACCESS; END-POINTS; INTERFERON ALPHA-2A; 2ND-LINE THERAPY; OPEN-LABEL; EFFICACY; CANCER; SAFETY;
D O I
10.1186/s12885-016-3016-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: To compare the efficacy of sorafenib and sunitinib with regard to overall survival (OS) and progression free survival (PFS) in Chinese patients with metastatic renal cell carcinoma (mRCC). Methods: A multicenter, retrospective study was performed to elucidate the relationship between clinical variables and prognosis comparing sorafenib and sunitinib as first-line treatment agents in Chinese patients with mRCC. Between September 2006 and December 2014, 845 patients received either sorafenib (400 mg bid; n = 483) or sunitinib (50 mg q.d; n = 362). The primary end point was OS and PFS. Results: The percentage of patients with low and moderate risk according to Memorial Sloan-Kettering Cancer Centre (MSKCC) score was significantly higher in sunitinib group, and that with high risk was significantly higher in sorafenib group (15.1 vs. 5.2%; p < 0.001). Median OS was similar in sorafenib and sunitinib group (24 vs. 24 months; p = 0.298). Sorafenib group exhibited higher mPFS compared to sunitinib group (11.1 vs. 10.0 months; p = 0.028). Treatment (sorafenib vs sunitinib), pathology, Eastern Cooperative Oncology Group (ECOG) performance status, MSKCC scores, Heng's criteria of risk, and number of metastases were identified as significant predictors for OS and along with liver metastasis for PFS. Clinical outcomes in terms of mOS was significantly better with sorafenib in patients >= 65 years of age (p = .041), ECOG 0 (p = 0.0001), and median MSKCC risk score (p = 0.008). Conclusions: Sorafenib and sunitinib are both effective in treating mRCC. However, sorafenib might be more effective in elderly patients (>= 65 years) and in patients with an ECOG status of 0, classified under MSKCC moderate risk.
引用
收藏
页数:10
相关论文
共 50 条
[31]   First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis [J].
Hahn, Andrew W. ;
Klaassen, Zachary ;
Agarwal, Neeraj ;
Haaland, Benjamin ;
Esther, John ;
Ye, Xiang Y. ;
Wang, Xuechen ;
Pal, Sumanta K. ;
Wallis, Christopher J. D. .
EUROPEAN UROLOGY ONCOLOGY, 2019, 2 (06) :708-715
[32]   Significance of introduction of alternative dosing schedule for sunitinib during first-line treatment of patients with metastatic renal cell carcinoma [J].
Miyake, Hideaki ;
Matsushita, Yuto ;
Watanabe, Hiromitsu ;
Tamura, Keita ;
Suzuki, Takahisa ;
Motoyama, Daisuke ;
Ito, Toshiki ;
Sugiyama, Takayuki ;
Otsukav, Atsushi .
MEDICAL ONCOLOGY, 2018, 35 (10)
[33]   Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma [J].
R J Motzer ;
B Escudier ;
R Bukowski ;
B I Rini ;
T E Hutson ;
C H Barrios ;
X Lin ;
K Fly ;
E Matczak ;
M E Gore .
British Journal of Cancer, 2013, 108 :2470-2477
[34]   Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma [J].
Barrios, Carlos H. ;
Hernandez-Barajas, David ;
Brown, Michael P. ;
Lee, Se-Hoon ;
Fein, Luis ;
Liu, Jin-Hwang ;
Hariharan, Subramanian ;
Martell, Bridget A. ;
Yuan, Jinyu ;
Bello, Akintunde ;
Wang, Zhixiao ;
Mundayat, Rajiv ;
Rha, Sun-Young .
CANCER, 2012, 118 (05) :1252-1259
[35]   Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma [J].
Atkins, Michael B. ;
Tannir, Nizar M. .
CANCER TREATMENT REVIEWS, 2018, 70 :127-137
[36]   Sunitinib: the First to Arrive at First-Line Metastatic Renal Cell Carcinoma [J].
Sergio Vázquez ;
Luis León ;
Ovidio Fernández ;
Martín Lázaro ;
Enrique Grande ;
Luis Aparicio .
Advances in Therapy, 2012, 29 :202-217
[37]   Comparative Efficacy, Safety, and Costs of Sorafenib vs. Sunitinib as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis [J].
Deng, Huan ;
Liu, Wenfeng ;
He, Ting ;
Hong, Zhengdong ;
Yi, Fengming ;
Wei, Yiping ;
Zhang, Wenxiong .
FRONTIERS IN ONCOLOGY, 2019, 9
[38]   Hilar fat infiltration: A new prognostic factor in metastatic clear cell renal cell carcinoma with first-line sunitinib treatment [J].
Kammerer-Jacquet, Solene-Florence ;
Brunot, Angelique ;
Bensalah, Karim ;
Campillo-Gimenez, Boris ;
Lefort, Mathilde ;
Bayat, Sahar ;
Ravaud, Alain ;
Dupuis, Frantz ;
Yacoub, Mokrane ;
Verhoest, Gregory ;
Peyronnet, Benoit ;
Mathieu, Romain ;
Lespagnol, Alexandra ;
Mosser, Jean ;
Edeline, Julien ;
Laguerre, Brigitte ;
Bernhard, Jean-Christophe ;
Rioux-Leclercq, Nathalie .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2017, 35 (10) :603.e7-603.e14
[39]   Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma-Analysis Using Diagnostic Nodes [J].
Rothermundt, Christian ;
Bailey, Alexandra ;
Cerbone, Linda ;
Eisen, Tim ;
Escudier, Bernard ;
Gillessen, Silke ;
Gruenwald, Viktor ;
Larkin, James ;
McDermott, David ;
Oldenburg, Jan ;
Porta, Camillo ;
Rini, Brian ;
Schmidinger, Manuela ;
Sternberg, Cora ;
Putora, Paul M. .
ONCOLOGIST, 2015, 20 (09) :1028-1035
[40]   Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial [J].
Zhou, Ai-Ping ;
Bai, Yuxian ;
Song, Yan ;
Luo, Hong ;
Ren, Xiu-Bao ;
Wang, Xiuwen ;
Shi, Benkang ;
Fu, Cheng ;
Cheng, Ying ;
Liu, Jiyan ;
Qin, Shukui ;
Li, Jun ;
Li, Hanzhong ;
Bai, Xianzhong ;
Ye, Dingwei ;
Wang, Jinwan ;
Ma, Jianhui .
ONCOLOGIST, 2019, 24 (08) :E702-E708